Literature DB >> 32642324

Technology-enabled assessments to enhance multiple sclerosis clinical care and research.

Gabrielle Macaron1, Brandon P Moss1, Hong Li1, Laura E Baldassari1, Stephen M Rao1, David Schindler1, Jay L Alberts1, Malory Weber1, Malissa Ayers1, François Bethoux1, Adrienne Boissy1, Desiree Chizmadia1, Devon S Conway1, Charlene Fink1, Robert J Fox1, Shauna Gales1, Bethany Green1, Claire Hara-Cleaver1, Neal Jordan1, Kedar R Mahajan1, Marisa P McGinley1, Deborah M Miller1, Marie Namey1, Alexander Rae-Grant1, Mary Rensel1, Hilary Young1, Mary A Willis1, Daniel Ontaneda1, Jeffrey A Cohen1, Robert A Bermel1.   

Abstract

BACKGROUND: Comprehensive and efficient assessments are necessary for clinical care and research in chronic diseases. Our objective was to assess the implementation of a technology-enabled tool in MS practice.
METHOD: We analyzed prospectively collected longitudinal data from routine multiple sclerosis (MS) visits between September 2015 and May 2018. The MS Performance Test, comprising patient-reported outcome measures (PROMs) and neuroperformance tests (NPTs) self-administered using a tablet, was integrated into routine care. Descriptive statistics, Spearman correlations, and linear mixed-effect models were used to examine the implementation process and relationship between patient characteristics and completion of assessments.
RESULTS: A total of 8022 follow-up visits from 4199 patients (median age 49.9 [40.2-58.8] years, 32.1% progressive course, and median disease duration 13.6 [5.9-22.3] years) were analyzed. By the end of integration, the tablet version of the Timed 25-Foot Walk was obtained in 89.0% of patients and the 9-Hole Peg Test in 94.8% compared with 74.2% and 64.3%, respectively before implementation. The greatest increase in data capture occurred in processing speed and low-contrast acuity assessments (0% prior vs 78.4% and 36.7%, respectively, following implementation). Four PROMs were administered in 41%-98% of patients compared with a single depression questionnaire with a previous capture rate of 70.6%. Completion rates and time required to complete each NPT improved with subsequent visits. Younger age and lower disability scores were associated with shorter completion time and higher completion rates.
CONCLUSIONS: Integration of technology-enabled data capture in routine clinical practice allows acquisition of comprehensive standardized data for use in patient care and clinical research.
© 2019 American Academy of Neurology.

Entities:  

Year:  2020        PMID: 32642324      PMCID: PMC7292568          DOI: 10.1212/CPJ.0000000000000710

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  26 in total

1.  Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Authors:  J A Cohen; G R Cutter; J S Fischer; A D Goodman; F R Heidenreich; M F Kooijmans; A W Sandrock; R A Rudick; J H Simon; N A Simonian; E C Tsao; J N Whitaker
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

2.  Processing speed test: Validation of a self-administered, iPad®-based tool for screening cognitive dysfunction in a clinic setting.

Authors:  Stephen M Rao; Genna Losinski; Lyla Mourany; David Schindler; Bernadett Mamone; Christine Reece; Danielle Kemeny; Sridar Narayanan; Deborah M Miller; Francois Bethoux; Robert A Bermel; Richard Rudick; Jay Alberts
Journal:  Mult Scler       Date:  2017-01-12       Impact factor: 6.312

Review 3.  Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis.

Authors:  Maria A Rocca; Maria P Amato; Nicola De Stefano; Christian Enzinger; Jeroen J Geurts; Iris-K Penner; Alex Rovira; James F Sumowski; Paola Valsasina; Massimo Filippi
Journal:  Lancet Neurol       Date:  2015-02-04       Impact factor: 44.182

4.  Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Authors:  J A Cohen; G R Cutter; J S Fischer; A D Goodman; F R Heidenreich; A J Jak; J E Kniker; M F Kooijmans; J M Lull; A W Sandrock; J H Simon; N A Simonian; J N Whitaker
Journal:  Arch Neurol       Date:  2001-06

5.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.

Authors:  David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays
Journal:  J Clin Epidemiol       Date:  2010-08-04       Impact factor: 6.437

6.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Authors:  G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

Review 7.  Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Authors:  Carmen Tur; Marcello Moccia; Frederik Barkhof; Jeremy Chataway; Jaume Sastre-Garriga; Alan J Thompson; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2018-01-12       Impact factor: 42.937

8.  Assessing disability progression with the Multiple Sclerosis Functional Composite.

Authors:  R A Rudick; C H Polman; J A Cohen; M K Walton; A E Miller; C Confavreux; F D Lublin; M Hutchinson; P W O'Connor; S R Schwid; L J Balcer; F Lynn; M A Panzara; A W Sandrock
Journal:  Mult Scler       Date:  2009-08       Impact factor: 6.312

9.  Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.

Authors:  S A Gauthier; B I Glanz; M Mandel; Antonios Tsagkaropoulos; Mohit Neema; James Stankiewicz; Ashish Arora; Yang Duan; Zsuzsanna Liptak; Svetlana Egorova; Guy J Buckle; Rohit Bakshi; C R G Guttmann; S J Khoury; H L Weiner
Journal:  J Neurol Sci       Date:  2009-05-09       Impact factor: 3.181

10.  The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool.

Authors:  Richard A Rudick; Deborah Miller; Francois Bethoux; Stephen M Rao; Jar-Chi Lee; Darlene Stough; Christine Reece; David Schindler; Bernadett Mamone; Jay Alberts
Journal:  J Vis Exp       Date:  2014-06-30       Impact factor: 1.355

View more
  4 in total

Review 1.  Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.

Authors:  Sajida Sabsabi; Elio Mikhael; Georges Jalkh; Gabrielle Macaron; Mary Rensel
Journal:  Patient Prefer Adherence       Date:  2022-05-24       Impact factor: 2.314

2.  Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic.

Authors:  Marisa P McGinley; Shauna Gales; William Rowles; Zhini Wang; Wan-Yu Hsu; Lilyana Amezcua; Riley Bove
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-02-25

Review 3.  Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review.

Authors:  Lynsey Lakin; Bryan E Davis; Cherie C Binns; Keisha M Currie; Mary R Rensel
Journal:  Neurol Ther       Date:  2021-04-20

4.  The Microsoft HoloLens 2 Provides Accurate Measures of Gait, Turning, and Functional Mobility in Healthy Adults.

Authors:  Mandy Miller Koop; Anson B Rosenfeldt; Kelsey Owen; Amanda L Penko; Matthew C Streicher; Alec Albright; Jay L Alberts
Journal:  Sensors (Basel)       Date:  2022-03-04       Impact factor: 3.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.